From targeted assays for C. difficile to broad disease state panels covering community-acquired and persistent diarrhea pathogens, clinical labs need flexibility and scalability in their GI assays to deliver optimal results to physicians for patient care, antimicrobial stewardship, and infection control.
That’s why Luminex offers targeted diagnostic options for nosocomial diarrhea and syndromic panels for community acquired/traveler’s diarrhea that align with recommended guidelines. These molecular solutions offer improved clinical outcomes when compared to traditional culture methods. In addition, the flexibility empowers clinical laboratories to improve efficiency by reducing turnaround time, consolidating sample testing, and reducing opportunities for human error. Overall, these solutions can help clinical labs generate actionable results while reducing costs.
Our gastrointestinal testing platforms are scalable to fit low-volume labs, high-capacity reference labs, and everything in between.
Learn more about our gastrointestinal disease testing options:
|Which Test is Right for You?|
(Community-Acquired / Persistent Diarrhea)
|Assay||ARIES® C. difficile Assay||xTAG™ GPP RUO 胃腸病原体検出キット|
|2 hours||5 hours|
per 24 samples
|Throughput||Low – Medium||High|
Clinical Labs Streamline GI Testing with MDx — MLO Online Article
Clinical Use of BI/NAP1/027 Detection — White Paper